RxDoctor Payments Data

Mary Tanyel, MD

Family Medicine · New Castle, PANPI 1790726925

Payments from drug & device makers

$8,716in general payments, 2019–2025

Across 539 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$875
  • Pfizer$859
  • AbbVie$836
  • GSK$453
  • Amgen$380
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$8,63199%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,716 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$73,382
Medicare patients
175
Services billed
833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban191$167,978
JardianceEmpagliflozin116$131,104
OzempicSemaglutide86$113,237
MounjaroTirzepatide69$95,406
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$58,215
XareltoRivaroxaban37$56,014
Repatha SureclickEvolocumab85$52,348
TradjentaLinagliptin54$48,502
GlyxambiEmpagliflozin/Linagliptin50$45,933
ProliaDenosumab25$42,844
TrulicityDulaglutide24$40,022
RybelsusSemaglutide23$37,585
MyrbetriqMirabegron60$33,980
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr52$31,965
FarxigaDapagliflozin Propanediol28$31,494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Synjardy Xr, Spiriva Respimat$191$249,215255 claims
PfizerEliquis, Premarin, Prempro$859$185,145226 claims
Novo NordiskOzempic, Rybelsus$1,756$150,822109 claims
Lilly USA, LLCMounjaro, Trulicity$875$135,42893 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$453$98,840137 claims
Johnson & JohnsonXarelto$107$56,01437 claims
AmgenProlia$380$42,84425 claims
AstraZenecaFarxiga, Breztri Aerosphere$338$41,83542 claims
Astellas Pharma US IncMyrbetriq$53$33,98060 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$33$24,41620 claims
NovartisEntresto$214$23,81125 claims
AbbVieLinzess, Synthroid$836$21,780136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in New Castle

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →